Literature DB >> 10910938

A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT.

B Nikolic1, G Zhao, K Swenson, M Sykes.   

Abstract

The treatment of mice with anti-CD4 and anti-CD8 monoclonal antibodies (mAbs) on day -5, plus 3 Gy whole body irradiation (WBI) and 7 Gy thymic irradiation (TI) on day 0, allows fully major-histocompatibility-complex-mismatched allogeneic bone marrow engraftment and the induction of immunologic tolerance. TI is required in this model to overcome alloreactivity and possibly to make "space" in the recipient thymus so that lasting central tolerance can be achieved. In addition to suppressing mature T cells in the periphery, Cyclosporine A (CYA) and glucocorticoids have a powerful influence on the thymus. In this study, we evaluated whether the administration of CYA to recipient mice for 12 days prior to bone marrow transplant (BMT), of glucocorticosteroids on the day of BMT, or a combination of both, could create space and overcome alloresistance in the thymus by specifically depleting immature and mature thymocytes prior to BMT. High levels of multilineage donor hematopoietic repopulation and specific transplantation tolerance were achieved in mice treated from days -15 to -3 with CYA (20 mg/kg/d subcutaneously), anti-CD4/CD8 mAbs on day -5, followed by 3 Gy WBI and 15 x 10(6) allogeneic bone marrow cells on day 0. Vbeta analysis suggested a central deletional tolerance mechanism. The same treatment without CYA pretreatment allowed only transient chimerism, without tolerance. Corticosteroid treatment abolished the engraftment-promoting and tolerance-inducing effects of CYA. These results demonstrate a novel pretransplantation-only application of CYA, which facilitates allogeneic marrow engraftment with minimal conditioning, by creating thymic space and/or overcoming intrathymic alloresistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910938

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Authors:  Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins.

Authors:  V D K D Sewgobind; L J W van der Laan; M M L Kho; R Kraaijeveld; S S Korevaar; W Mol; W Weimar; C C Baan
Journal:  Clin Exp Immunol       Date:  2010-05-28       Impact factor: 4.330

3.  Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.

Authors:  Benson M George; Kevin S Kao; Hye-Sook Kwon; Brenda J Velasco; Jessica Poyser; Angela Chen; Alan C Le; Akanksha Chhabra; Cassandra E Burnett; Devon Cajuste; Malachia Hoover; Kyle M Loh; Judith A Shizuru; Irving L Weissman
Journal:  Cell Stem Cell       Date:  2019-06-13       Impact factor: 24.633

Review 4.  Immune monitoring of transplant patients in transient mixed chimerism tolerance trials.

Authors:  Megan Sykes
Journal:  Hum Immunol       Date:  2017-12-28       Impact factor: 2.850

5.  Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice.

Authors:  Boris Nikolic; Takashi Onoe; Yasuo Takeuchi; Zain Khalpey; Valeria Primo; Igor Leykin; R Neal Smith; Megan Sykes
Journal:  Transplantation       Date:  2010-01-15       Impact factor: 4.939

6.  Inflammatory cells' role in acetic acid-induced colitis.

Authors:  Mohammad H Sanei; Fatemeh Hadizadeh; Peyman Adibi; Sayyed Ali Alavi
Journal:  Adv Biomed Res       Date:  2014-09-23

7.  Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT.

Authors:  A Toor; T Rodriguez; M Bauml; H Mathews; S Shanti; D Senitzer; A Kini; J Norton; M Parthasarathy; N Mohideen; C Petrowsky; B Bonilla; S Smith; P Stiff
Journal:  Bone Marrow Transplant       Date:  2008-08-18       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.